What is the confirmed market size and growth trajectory for the equine healthcare market?

The market was valued at USD 4.9 billion in 2025 and is projected to grow at a CAGR of 11.2% to USD 12.74 billion by 2035. Vaccines are the dominant product category. NSAIDs and pain management are the second-largest category. Anti-infectives are significant. North America leads; Asia-Pacific grows fastest from expanding equestrian sport adoption. Competition horses generate the highest per-animal spending.

How does Core EQ Innovator define the equine vaccine market opportunity?

Core EQ Innovator — the first 5-antigen combination equine core vaccine — simplifies the veterinarian’s equine vaccination programme by eliminating the need to separately administer up to five individual vaccines per horse per year. The combination product improves vaccine compliance, reduces administration time and animal stress, and creates a premium-priced convenience advantage over multi-product protocols that has sustained its position in the equine vaccine market since 2018 U.S. approval and 2019 Canadian approval.

What pharmaceutical categories are growing fastest in equine healthcare?

Equine pain management is the fastest-growing pharmaceutical category — driven by the same recognition that has made Librela commercially successful in dogs — that chronic orthopaedic pain in horses is undertreated by conventional short-term NSAID approaches. Firocoxib (Equioxx), the first equine selective COX-2 inhibitor, and emerging equine biologics for OA pain represent the innovation frontier of equine pain management. Equine dermatology and respiratory medicine are also growing as horse owners invest in managing chronic conditions at human-equivalent clinical standards.

How does equine reproductive medicine create a specialist veterinary market segment?

Equine reproductive medicine — encompassing ovulation induction (hCG, deslorelin), estrus synchronisation, artificial insemination, embryo transfer, and stallion reproductive management — generates premium reproductive pharmaceutical and veterinary service revenue from breeding operations whose financial investment in valuable mares and stallions justifies intensive reproductive management. Thoroughbred racing breeding economics create the highest-value equine reproductive medicine applications globally.

How does the global growth of equestrian sport create equine health market expansion?

Equestrian sport participation is growing in China, South Korea, the UAE, Saudi Arabia, and Southeast Asia — markets where equestrian activity has expanded from elite sport to lifestyle equestrian activity among growing middle-class populations. These new equestrian markets create new equine health product and veterinary service demand across core vaccination, parasite control, and performance medicine categories above established North American and European market replacement cycles.

How does equine parasite resistance management create specialised antiparasitic demand?

Anthelmintic resistance in equine cyathostomins (small strongyles) is a global challenge that makes resistance testing before treatment selection — fecal egg count monitoring, larval development assays — increasingly standard in evidence-based equine parasite management. This testing paradigm creates recurring diagnostic service demand alongside antiparasitic product sales, and sustains demand for novel mechanism anthelmintics as resistance to benzimidazoles and pyrantel grows.